Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Ponzetti C, Canciani M, Farina M, Era S, Walzer S. ClinicoEconomics and Outcomes Research. 2016;8:227–233.
On page 230, Table 3, first column: The last time component should be: “Patient preparation time for eighteen cycles of therapy in oncology (breast cancer)”.
On page 231, Table 4, first column: The second rituximab preparation item should be: “Median time to prepare rituximab (for median number of patients per day)”.
On page 231, Table 4, first column: The third item should be: “Median time to prepare trastuzumab (for each patient with eighteen therapeutic administrations)”.
On page 231, Table 4, first column: The last trastuzumab preparation item should be: “Median time to prepare trastuzumab (for median number of patients per day)”.
On page 232, Table 5, first column: Wording of the last outcome for each therapy should be: “Annual economic impact” rather than “Annual economic impact per patient”.
On page 232, Table 5, second column: “In breast cancer (trastuzumab)”, the mean annual economic impact for the intravenous administration should be: €29,872.
On page 232, Table 5, second column: The public price (hospital price) for subcutaneous administration should be: €2.89/mg.
Read the original article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]